Green Cross Holdings invested in an American bio venture to develop gene therapy

Published: 2015-05-15 09:52:17

Updated: 2015-05-15 09:52:17

Green Cross Holdings (President Byung-geon Lee) announced on the 14^th that it has participated in the Series B-2 Round of the American bio venture ‘Juventas Therapeutics(hereinafter referring to Juventas)’ as quota investment worth of $7.5 million along with an affiliated investment company, Posco Capital.

Juventas, a bio venture associated with the world’s best cardiovascular disease treatmen...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.